China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.
China Resources Double-Crane Pharmaceutical Co., Ltd. has reported its unaudited financial results for the first half of 2024, showing a modest revenue increase of 1.46% and a more substantial rise in net profit by 6.28%. Despite the overall positive performance, total assets and net assets attributable to shareholders fell by 11.52% and 18.66%, respectively. Investors are advised to approach the company’s interim report with caution, as it has not been audited and does not reflect the full financial situation of the parent group.
For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.
